Edwards Lifesciences Corporation (EW) continues to pique the interest of institutional investors, accounting for 88% of ownership. While Alberta Investment Management Corp and Vanguard Group Inc expanded their stake in the company, some entities such as BI Asset Management Fondsmaeglerselskab A S and Azzad Asset Management Inc. followed the same path. Meanwhile, Shell Asset Management Co and Envestnet Asset Management Inc. trimmed their holdings. The strong investor interest can be attributed to expectations of a
renewed growth cycle from
analysts and their bullish sentiment. The company's
Q4 2025 earnings call, despite missing the EPS forecast, drew positive reactions with potential for a price correction given the sound financials. However, Edwards Lifesciences also experienced a decline on the back of squeezed margins in 2025 and a
cautious 2026 EPS outlook. Amid this, the company's Q1 2026 revenue is projected to be between $1.55 billion and $1.63 billion. The termination of the
EU antitrust probe instigated a surge in the share price.
New initiatives such as the updated guidelines for severe aortic stenosis (AS) demonstrate the company's continuous efforts to innovate. Additionally, Wall Street maintains a 'Moderate Buy' rating for the stock.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Fri, 20 Feb 2026 13:19:36 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor -2
